Roadblocks to Information Exchange

August, 2011

There's no question that non-profit organizations are looked to by many - patients, journalists and even policymakers - as a source of credible, relevant information. Forward-thinking pharmaceutical companies understand this and often seek patient advocates as partners for education and awareness.

So, why is it that Industry and advocates alike routinely cite information exchange as one of the biggest hurdles to working together? Where's the roadblock?

The truth is that both parties are sometimes hamstrung by barriers that inhibit the timely exchange of information. Here are a few tips to help keep the information in the fast lane:

Recognize the guardrails

It should be no surprise that there are rules around information exchange between advocacy groups and Industry. While information exchange in North America is relatively clear (you can look to PhRMA guidelines and the FDA for guidance), many nuances exist globally and can vary from country to country.

Use the fast lane

To be effective, advocates require timely information (to answer questions from their constituents and media). As often as possible, Industry should make advocates a priority audience, even if it requires the use of a confidentiality agreement.

Consider the alternate routes

Around the globe, Internet availability can sometimes be spotty. Be sure to consider information vehicles that live both on- and offline.

The most important thing to remember is that good relationships are built on honesty and trust. Communication between Industry and advocates should always be transparent, honest and straightforward. Learn more about the rules of the road for advocacy relations.